$THAR
Tharimmune, Inc. Stock $thar

$thar Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018338 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.374M	$1.322M	$1.667M
YoY Change	3.03%	-20.68%	59.75%
% of Gross Profit
Research & Development	$999.6K	$1.025M	$1.048M
YoY Change	-3.06%	-2.14%	240.34%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.373M	$2.347M	$2.714M
YoY Change	0.37%	-13.52%	100.89%
Operating Profit	-$2.373M	-$2.300M	-$2.700M
YoY Change	0.37%	-14.81%	99.83%
Interest Expense	$48.39K	$4.700K	$6.138K
YoY Change	642.52%	-23.43%	-100.39%
% of Operating Profit
Other Income/Expense, Net	$48.40K	$91.19K	$26.11K
YoY Change	74.83%	249.27%
Pretax Income	-$2.325M	-$2.256M	-$2.688M
YoY Change	-0.51%	-16.08%	-8.64%
Income Tax
% Of Pretax Income
Net Earnings	-$2.325M	-$2.256M	-$2.688M
YoY Change	-0.51%	-16.08%	-8.64%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.42	-$0.19	-$0.23
Diluted Earnings Per Share	-$2.42	-$0.19	-$0.23
COMMON SHARES
Basic Shares Outstanding	11.79M shares	11.74M shares	11.51M shares
Diluted Shares Outstanding	962.1K shares	11.76M shares	460.6K shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.896M	$8.427M	$3.569M
YoY Change	102.25%	136.11%	-67.91%
Cash & Equivalents	$7.896M	$8.427M	$3.569M
Short-Term Investments
Other Short-Term Assets	$361.6K	$460.0K	$1.153M
YoY Change	-48.0%	-60.09%	394.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.257M	$8.887M	$4.722M
YoY Change	79.53%	88.21%	-58.42%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$8.257M	$8.887M	$4.722M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$8.257M	$8.887M	$4.722M
YoY Change	79.53%	88.21%	-58.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$784.0K	$993.2K	$719.0K
YoY Change	-31.25%	38.14%	20.34%
Accrued Expenses	$579.5K	$527.5K	$242.2K
YoY Change	753.78%	117.79%	10.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$1.564M	$1.838M	$1.521M
YoY Change	2.17%	20.82%	49.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.564M	$1.838M	$1.521M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.564M	$1.838M	$1.521M
YoY Change	2.17%	20.82%	49.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.30M	-$27.00M	-$18.10M
YoY Change	43.63%	49.17%
Common Stock	$111.00	$1.180K	$1.160K
YoY Change	-93.43%	1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$69.97K	$69.97K	$69.97K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$6.694M	$7.049M	$3.201M
YoY Change
Total Liabilities & Shareholders Equity	$8.257M	$8.887M	$4.722M
YoY Change	79.53%	88.21%	-58.42%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.325M	-$2.256M	-$2.688M
YoY Change	-0.51%	-16.08%	-8.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.179M	-$2.800M	-$3.500M
YoY Change	44.23%	-20.0%	74.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.648M	$317.1K	$523.4K
YoY Change	-10.73%	-39.41%	-96.01%
NET CHANGE
Cash From Operating Activities	-2.179M	-$2.800M	-$3.500M
Cash From Investing Activities
Cash From Financing Activities	1.648M	$317.1K	$523.4K
Net Change In Cash	-531.4K	-$2.508M	-$2.941M
YoY Change	-258.71%	-14.73%
FREE CASH FLOW
Cash From Operating Activities	-$2.179M	-$2.800M	-$3.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11789676	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10935352	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11041	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10946393	usd
CY2023Q4	us-gaap	Assets Assets	10946393	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	908577	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	527527	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	906469	usd
CY2024Q1	THAR	Insurance Premium Financing Liability InsurancePremiumFinancingLiability	317119	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1815046	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1815046	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11793309	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11789676	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1175	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33903663	usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001861657
CY2023Q4	THAR	Insurance Premium Financing Liability InsurancePremiumFinancingLiability		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
CY2024Q1	THAR	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41210
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	THARIMMUNE, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2642541
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Route 22 East
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2024Q1	dei	City Area Code CityAreaCode	(908)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	270-8260
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	THAR
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11789676	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10935352	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11041	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8887297	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10946393	usd
CY2024Q1	us-gaap	Assets Assets	8887297	usd
CY2023Q4	us-gaap	Assets Assets	10946393	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	993244	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	908577	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	906469	usd
CY2024Q1	THAR	Insurance Premium Financing Liability InsurancePremiumFinancingLiability	317119	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24703526	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3633	shares
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1815046	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1815046	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11743309	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11789676	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11739676	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1175	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34077827	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33903663	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26959635	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24703526	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3633	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3633	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	69965	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	69965	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10946393	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1025258	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1047677	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1322045	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1666721	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2714398	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2347303	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2714398	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	4700	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	6138	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	95894	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	32248	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91194	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26110	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.84
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.84
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11757808	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11757808	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	460580	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	460580	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5543655	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	69965	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7049407	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1025258	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1047677	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1322045	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1666721	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2347303	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2714398	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2347303	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2714398	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	4700	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	6138	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	95894	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	32248	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91194	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26110	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.84
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.84
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11757808	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	460580	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5543655	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	345432	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3200799	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20550	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	153619	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7049407	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	153619	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20550	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	448966	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	892964	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	84667	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-280622	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-378942	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	51752	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2825181	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3464690	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	36553	usd
CY2024Q1	THAR	Proceeds From Insurance Premium Financing Liability ProceedsFromInsurancePremiumFinancingLiability	393960	usd
CY2023Q1	THAR	Proceeds From Insurance Premium Financing Liability ProceedsFromInsurancePremiumFinancingLiability	716775	usd
CY2024Q1	THAR	Repayment Of Insurance Premium Financing Liability RepaymentOfInsurancePremiumFinancingLiability	76841	usd
CY2023Q1	THAR	Repayment Of Insurance Premium Financing Liability RepaymentOfInsurancePremiumFinancingLiability	156858	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	345432	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3200799	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9131347	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20550	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	153619	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7049407	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7049407	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2256109	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2688288	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	153619	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	345432	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20550	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	448966	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	892964	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	84667	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-280622	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-378942	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	51752	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2825181	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	36553	usd
CY2024Q1	THAR	Proceeds From Insurance Premium Financing Liability ProceedsFromInsurancePremiumFinancingLiability	393960	usd
CY2023Q1	THAR	Proceeds From Insurance Premium Financing Liability ProceedsFromInsurancePremiumFinancingLiability	716775	usd
CY2024Q1	THAR	Repayment Of Insurance Premium Financing Liability RepaymentOfInsurancePremiumFinancingLiability	76841	usd
CY2023Q1	THAR	Repayment Of Insurance Premium Financing Liability RepaymentOfInsurancePremiumFinancingLiability	156858	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	317119	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2508062	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2941326	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10935352	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6510534	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8427290	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3569208	usd
CY2023Q1	THAR	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts	45107	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2300000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2800000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27000000.0	usd
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2100000	usd
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	8700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zmiAXZSr3Njk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_863_zDyJp5rMnuH2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the condensed consolidated financial statements where estimates may have the most significant effect include research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	THAR	Insurance Premium InsurancePremium	955700	usd
CY2023Q1	THAR	Insurance Premium Financing Interest Rate Percentage InsurancePremiumFinancingInterestRatePercentage	0.0525	pure
CY2023Q1	THAR	Payments To Insurance Premium Financing Liability PaymentsToInsurancePremiumFinancingLiability	238925	usd
CY2023Q1	THAR	Insurance Premium Interest Amount InsurancePremiumInterestAmount	81394	usd
CY2024Q1	THAR	Insurance Premium Financing Interest Rate Percentage InsurancePremiumFinancingInterestRatePercentage	0.075	pure
CY2024Q1	THAR	Payments To Insurance Premium Financing Liability PaymentsToInsurancePremiumFinancingLiability	98490	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	317119	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	523364	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2508062	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2941326	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10935352	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6510534	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8427290	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3569208	usd
CY2023Q1	THAR	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts	45107	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2300000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2800000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27000000.0	usd
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2100000	usd
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	8700000	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2024Q1	THAR	Insurance Premium Interest Amount InsurancePremiumInterestAmount	40763	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	369337	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zbxPE9hpQloa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_862_zUzUEu0DSDB6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zfALuEjbfdY6" title="FDIC insured amount">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2023Q1	THAR	Sale Of Stock Shelf Registration Maximum SaleOfStockShelfRegistrationMaximum	75000000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zbxPE9hpQloa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_862_zUzUEu0DSDB6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zfALuEjbfdY6" title="FDIC insured amount">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	THAR	Insurance Premium InsurancePremium	955700	usd
CY2023Q1	THAR	Insurance Premium Financing Interest Rate Percentage InsurancePremiumFinancingInterestRatePercentage	0.0525	pure
CY2023Q1	THAR	Payments To Insurance Premium Financing Liability PaymentsToInsurancePremiumFinancingLiability	238925	usd
CY2023Q1	THAR	Insurance Premium Interest Amount InsurancePremiumInterestAmount	81394	usd
CY2024Q1	THAR	Insurance Premium InsurancePremium	492450	usd
CY2024Q1	THAR	Insurance Premium Financing Interest Rate Percentage InsurancePremiumFinancingInterestRatePercentage	0.075	pure
CY2024Q1	THAR	Payments To Insurance Premium Financing Liability PaymentsToInsurancePremiumFinancingLiability	98490	usd
CY2024Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	337	usd
CY2023Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1819	usd
CY2023Q1	THAR	Sale Of Stock Shelf Registration Maximum SaleOfStockShelfRegistrationMaximum	75000000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90758	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80.30
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	77187	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	76.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	90758	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	80.30
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.951	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0399	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	9.75
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	337	usd
CY2023Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1819	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90758	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90758	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80.30
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	77187	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	76.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	90758	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	80.30
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.951	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0399	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	9.75
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.75
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	80.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	14.16
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	153619	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.75
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	80.51
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	14.16
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	153619	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	345432	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1100000	usd
CY2023Q1	THAR	Upfront Payment UpfrontPayment	150000	usd
CY2023Q1	THAR	Milestone Payment MilestonePayment	1000000	usd
CY2024Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	50000	usd
CY2024Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	50000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	345432	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1100000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2023Q2	THAR	Number Of Securities Sold Percentage NumberOfSecuritiesSoldPercentage	0.03	pure
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.625
CY2023Q1	THAR	Upfront Payment UpfrontPayment	150000	usd
CY2023Q1	THAR	Milestone Payment MilestonePayment	1000000	usd
CY2024Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	50000	usd
CY2024Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	50000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-018338-index-headers.html	Edgar Link	pending
0001493152-24-018338-index.html	Edgar Link	pending
0001493152-24-018338.txt	Edgar Link	pending
0001493152-24-018338-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thar-20240331.xsd	Edgar Link	pending
thar-20240331_cal.xml	Edgar Link	unprocessable
thar-20240331_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
0001493152-24-018338-index-headers.html	Edgar Link	pending
0001493152-24-018338-index.html	Edgar Link	pending
0001493152-24-018338.txt	Edgar Link	pending
0001493152-24-018338-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thar-20240331.xsd	Edgar Link	pending
thar-20240331_cal.xml	Edgar Link	unprocessable
thar-20240331_def.xml	Edgar Link	unprocessable
thar-20240331_lab.xml	Edgar Link	unprocessable
thar-20240331_pre.xml	Edgar Link	unprocessable
thar-20240331_pre.xml	Edgar Link	unprocessable
thar-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THAR
Tharimmune, Inc. Stock $thar

2024 Q2 Form 10-Q Financial Statement

#000149315224018338 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR Tharimmune, Inc. Stock $thar

2024 Q2 Form 10-Q Financial Statement

#000149315224018338 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR
Tharimmune, Inc. Stock $thar